The current PE ratio of SRPT can't be determined, as the TTM EPS of -$2.51 is negative. The last PE ratio of Sarepta Therapeutics, recorded in December 2024, was 49.23.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 49.23 | N/A | $121.59 | $2.47 |
2023 | N/A | N/A | $96.43 | -$5.8 |
2022 | N/A | N/A | $129.58 | -$8.03 |
2021 | N/A | N/A | $90.05 | -$5.15 |
2020 | N/A | N/A | $170.49 | -$7.11 |
2019 | N/A | N/A | $129.04 | -$9.71 |
2018 | N/A | N/A | $109.13 | -$5.46 |
2017 | N/A | N/A | $55.64 | -$0.86 |
2016 | N/A | N/A | $27.43 | -$5.49 |
2015 | N/A | N/A | $38.58 | -$5.2 |
2014 | N/A | N/A | $14.47 | -$3.39 |
2013 | N/A | N/A | $20.37 | -$3.31 |
2012 | N/A | N/A | $25.8 | -$5.14 |
2011 | N/A | N/A | $4.47 | -$0.11 |
2010 | N/A | N/A | $12.72 | -$1.74 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | N/A | N/A | $63.82 | -$2.51 |
Dec 2024 | 49.23 | -38.51% | $121.59 | $2.47 |
Sep 2024 | 80.06 | -62% | $124.89 | $1.56 |
Jun 2024 | 210.67 | -33.28% | $158 | $0.75 |
Mar 2024 | 315.76 | N/A | $129.46 | $0.41 |
Dec 2023 | N/A | N/A | $96.43 | -$5.8 |
Sep 2023 | N/A | N/A | $121.22 | -$7.83 |
Jun 2023 | N/A | N/A | $114.52 | -$10.31 |
Mar 2023 | N/A | N/A | $137.83 | -$12.69 |
Dec 2022 | N/A | N/A | $129.58 | -$8.03 |
Sep 2022 | N/A | N/A | $110.54 | -$8.22 |
Jun 2022 | N/A | N/A | $74.96 | -$5.88 |
Mar 2022 | N/A | N/A | $78.12 | -$4.25 |
Dec 2021 | N/A | N/A | $90.05 | -$5.15 |
Sep 2021 | N/A | N/A | $92.48 | -$6.13 |
Stock name | PE ratio | Market cap |
---|---|---|
NVAX Novavax Inc | 2.36 | $1.16B |
PTCT Ptc Therapeutics Inc | 6.76 | $4.05B |
GILD Gilead Sciences Inc | 22.86 | $135.61B |
BCRX Biocryst Pharmaceuticals Inc | N/A | $2.31B |
ALNY Alnylam Pharmaceuticals Inc | N/A | $39.81B |
RNA Avidity Biosciences Inc | N/A | $4.12B |
INSM INSMED Inc | N/A | $13.42B |
SRPT Sarepta Therapeutics Inc | N/A | $3.89B |
The current price to earnings ratio of SRPT can't be calculated, as its EPS of -$2.51 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.